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Abstract
Background: Despite the importance of the mucosal interface between microbiota and the host in gut homeostasis,
little is known about the mechanisms of bacterial gut colonization, involving foraging for glycans produced by
epithelial cells. The slow pace of progress toward understanding the underlying molecular mechanisms is largely due
to the lack of efficient discovery tools, especially those targeting the uncultured fraction of the microbiota.
Results: Here, we introduce an ultra-high-throughput metagenomic approach based on droplet microfluidics,
to screen fosmid libraries. Thousands of bacterial genomes can be covered in 1 h of work, with less than ten
micrograms of substrate. Applied to the screening of the mucosal microbiota for β-N-acetylgalactosaminidase
activity, this approach allowed the identification of pathways involved in the degradation of human gangliosides and
milk oligosaccharides, the structural homologs of intestinal mucin glycans. These pathways, whose prevalence is
associated with inflammatory bowel diseases, could be the result of horizontal gene transfers with Bacteroides species.
Such pathways represent novel targets to study the microbiota-host interactions in the context of inflammatory bowel
diseases, in which the integrity of the mucosal barrier is impaired.
Conclusion: By compartmentalizing experiments inside microfluidic droplets, this method speeds up and miniaturizes
by several orders of magnitude the screening process compared to conventional approaches, to capture entire
metabolic pathways from metagenomic libraries. The method is compatible with all types of (meta)genomic libraries,
and employs a commercially available flow cytometer instead of a custom-made sorting system to detect intracellular
or extracellular enzyme activities. This versatile and generic workflow will accelerate experimental exploration
campaigns in functional metagenomics and holobiomics studies, to further decipher host-microbiota relationships.
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Background
The intestinal ecosystem plays a major role in keeping
us healthy. Gut microbes interact with the host at the
mucosal barrier, which physically protects the intestinal
epithelium from direct contact with commensals, but
also constitutes a nutrient-rich micro-habitat. However,
excessive degradation of mucus, especially of the glycans
that decorate mucins, has a significant impact on sus-
ceptibility to pathogens. Alteration of the mucus layer is
also associated with inflammatory bowel diseases (IBD)
including Crohn’s disease and ulcerative colitis [1–5].
Experimental characterization of host-microbiota inter-
actions will help to understand the molecular mecha-
nisms leading to IBD better.
In order to metabolize the structurally diverse glycans
found in the intestine (host glycans, dietary glycans and,
to a minor extent, microbial exopolysaccharides), bacteria
produce a large panel of carbohydrate-active enzymes
(CAZymes), which can be secreted, cell-surface associated,
periplasmic or cytoplasmic [6, 7], and a battery of proteins
to specifically sense, bind and transport glycans into cells
for their complete breakdown. These metabolic machiner-
ies are often encoded by multigenic clusters [8], termed
polysaccharide utilization loci (PULs) in Bacteroidetes [9].
Several plant glycan utilization pathways from gut bacteria
have been characterized recently at the molecular level
([10–14] reviewed in [13]). However, biochemical studies
can only be carried out when structurally defined sub-
strates are available in large enough quantity. The diffi-
culty of providing sufficient amounts of material for
functional studies (hampered, e.g., by the high cost of
human-derived substrates and the non-trivial effort in-
volved in their synthesis) explains why only a handful of
mechanisms for the foraging of gut bacteria on human
glycans have been elucidated so far ([15–24] reviewed in
[13, 25]). Among them, only a few are related to the
metabolism of uncultured bacteria [17, 18, 24]. Bearing in
mind that uncultured species largely dominate in the
microbiota, the available evidence is far from exhaustive
and leaves much of the understanding of the inter-
relationships between the microbiota and their host to be
discovered.
Given the diversity of the human gut microbiome,
activity-based screening is an attractive strategy for the
functional exploration of whole microbiota. Such a func-
tional metagenomics approach simultaneously leads to
biochemical proof of function for the proteins involved
and links functions to sequences encoded by the meta-
genome. Indeed, mining the human gut microbiome has
led to the identification of CAZymes involved in the ca-
tabolism of plant-derived dietary glycans [8, 26, 27], of
crude mucus with a highly complex molecular structure
[28], and, more recently, in the conversion of the A- to
the H-antigen of O type blood [24]. The limits of this
approach are practical: automated screening of metage-
nomic libraries on agar plates or in micro-plates allows
only up to hundreds of thousands of assays per week to
be carried out [29]. In each of these conventional screen-
ing formats (liquid or solid), large amounts of substrate
(~grams) and liters of culture medium are required to
grow libraries of clones that are large enough to cover
sufficient sequence space to detect hits (> 103 Mbp) [8].
The miniaturization of screening volumes to picoliters
has been achieved by compartmentalizing individual
screening experiments in water-in-oil emulsion droplets
that are generated and sorted in microfluidic systems at
kHz rates. First used for directed enzyme evolution [30,
31], droplet microfluidics has been applied to discover mi-
crobes from environmental samples that secrete enzymes
[32] or to screen metagenomic DNA libraries for enzymes
performing non-natural reactions [33]. The latter study is
the first (and still only) example of an application of
droplet-based microfluidics in functional metagenomics.
The approach involved the lysis of metagenomic Escheri-
chia coli clones grown in single-cell emulsion droplets to
enable the encounter of intracellular enzymes with the
fluorogenic substrate. After on-chip sorting of the fluores-
cent droplets, the selected genes (as short metagenomic
DNA fragments of ~ 2 kbp cloned into a high copy num-
ber plasmid) can be recovered efficiently [31] after de-
emulsification and E. coli transformation. However, multi-
gene clusters and operons encoding entire anabolic or
catabolic pathways (such as the PULs involved in the
metabolization of complex glycans [8]) cannot be identi-
fied in such short fragments. The prospect of identifying
such complex systems rather than single enzymes will
make the microfluidic screening of libraries with larger
metagenomic DNA fragments (30 to 40 kbp) attractive.
The amount of DNA screened “per assay” in a “monoclo-
nal” droplet would be increased and a larger fraction of
sequence space will be explored. Our objective was there-
fore to develop a workflow compatible with the recovery
of large DNA fragments, typically involving low copy
number fosmid vectors instead of the previously used high
copy/small insert plasmid libraries [33]. We recently dem-
onstrated selective growth in single-emulsion droplets of
metagenomic clones, which are able to both internalize
and to metabolize oligosaccharides [34], and these two
properties are conferred to the host strain by a single PUL
cloned into a fosmid [35]. In this work, we demonstrated
that the metagenomic gene expression in fosmids is due
to the random presence of sequences on the metagenomic
DNA insert which are recognized as promoters by the E.
coli host strain [35]. For enzyme screening, the challenge
of protein expression has to be met, so various formats for
protein production in droplets have been developed, e.g.,
yeast display [30], in vitro expression [36], or expression
in E. coli followed by cell lysis [31]. Only the latter is
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compatible with the screening of a metagenomic library
and would cover intracellularly as well as extracellularly
expressed proteins. It was consequently used in the
present work. Our workflow for enzyme discovery from
metagenomes therefore starts with transformation of E.
coli with a fosmid library. Efficient enzyme expression and
recovery are key to the success of this approach: within
droplets both phenotype and genotype were amplified by
cell growth [37]. The previous metagenomic droplet
screening campaign [33] had used on-chip sorting, while
in this work we employed flow-cytometric sorting of
water-in-oil-in-water “double emulsion” droplets [38].
The throughput of both is similar (> 106 per day), but
FACS instruments are widely available to non-specialist
laboratories, thus avoiding the need to set up a specialized
laser sorting system [39].
This set-up constitutes the first ultra-high-throughput
screening pipeline for fosmid libraries but is compatible
with all types of (meta)genomic libraries (i.e., containing
short and large inserts) and allows the detection of intra-
cellular and extracellular enzyme activities. The ap-
proach was validated by exploring the human glycan
degrading potential of the gut mucosal microbiota,
which led to the identification of key pathways involved
in microbiota-host interaction in the context of IBD.
Results
A new pipeline for droplet-based microfluidic screening
of enzymes
This study focused on the microbiota of the distal ileum
mucosa, which is likely to play a role in the regulation of
intestinal homeostasis and immune response [40]. In-
deed, the terminal ileum is, as the rectum, an anatomical
region highly predisposed to inflammation in IBD [41,
42]. In addition, the diversity of the mucosa-associated
microbiota is relatively stable from the distal ileum to
the rectum, in both healthy individuals and patients with
IBD [43]. This analysis suggests that our sampling strat-
egy to study the relationships between the host and
mucosa-associated bacteria will cover this diversity, al-
though the glycosylation patterns of the mucus lining
the epithelium are different between the small and the
large intestine, with more fucosylated, and fewer sialy-
lated and sulfated glycans in the small intestine [44].
A metagenomic library of 20,000 fosmid E. coli clones,
covering 0.7 Gb of metagenomic DNA, was screened by
droplet microfluidics for β-N-acetylgalactosaminidase
(β-GalNAcase) activity using a commercially available
fluorogenic glycoside analog, resorufin-β-GalNAc, mim-
icking GalNAc-containing physiological substrates. In-
deed, GalNAc is one of the main components of human
glycans (e.g., mucus, gangliosides, milk, blood group an-
tigens), together with fucose (Fuc), sialic acid (Neu5Ac),
galactose (Gal), and glucose (Glc).
The workflow in Fig. 1 illustrates how single cells were
compartmentalized into monodisperse droplets accord-
ing to a Poisson distribution that gives an average of
0.35 cells per droplet to ensure mono-clonality (i.e.,
while 70.5% of all droplets were empty, 25% contained a
single clone, and 4.5% multiple clones). To visualize en-
zymatic turnover in droplets, resorufin-β-GalNAc was
added to the cells with a recovery medium before encap-
sulation. In the droplets, enzyme and substrate were
brought together by the partial and spontaneous lysis of
E. coli, where the liberated enzyme generated fluorescent
product. Cell division was also necessary to maintain
fully functional E. coli clones within each droplet and to
improve chances of fosmidic DNA recovery after droplet
sorting.
In order to determine the best screening conditions,
three incubation times (24, 48, or 72 h before sorting)
and two pHs (8 and 9) were tested to cover the likely ac-
tivity range over the timescale of the experiment, which
depends (i) on the kinetics of growth and spontaneous
lysis in droplets, and (ii) on resorufin-substrate leakage
at long incubation times. An experimental analysis was
necessary, because these factors contribute in opposing
directions, creating a challenge of identifying an
optimum. While cell growth and survival is expected to
be more efficient at pH 8 than at pH 9, the resorufin-
substrate leaks faster at pH 8 than at pH 9 (Fig. S1 in
Additional file 1) even though the fluorophore emits
higher fluorescence at pH 9.
For each sorting condition, at least 6 million droplets
were sorted by FACS, corresponding to a 90-fold over-
sampling coverage of the initial library diversity. A drop-
let fluorescence threshold of at least fivefold of the
fluorescence brought about by cellular and chemical
background (relative to a clone without β-GalNAcase ac-
tivity) was applied in the flow cytometric droplet sorting.
This tolerant threshold was deliberately chosen to avoid
loss of relevant clones, given the possible phenotypic
variation and variation in cell growth in droplets. The
yield of droplets satisfying this criterion varied between
0.02 and 0.06%, resulting in several thousand hit droplets
for each condition.
After sorting, the selected droplets were de-emulsified
and plated on agar for overnight growth. This allowed
us to recover the hit clones without any DNA recovery
and transformation steps. Under both pH conditions, a
48 h incubation time resulted in the best clone recovery
yield, specifically 179% at pH 8 and 100% at pH 9 (Table 1).
These high recoveries are due to cell growth during the
time of incubation. After growth, multiple occupancy of
droplets by identical clones makes recovery more likely.
The lower recovery yield obtained at pH 9 could be ex-
plained by the slower growth and survival rates at pH 9
compared to pH 8.
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Then, we further analyzed around 10% of the recov-
ered clones, in order to establish their functional profile
and to quantify false positives due to (i) the co-
encapsulation of multiple cells in one droplet at the
point of droplet generation (according to Poisson distri-
bution around 4.5% of the droplets contained more than
one cell at the initial incubation time) and (ii) the toler-
ant threshold chosen for cell sorting by FACS.
The β-GalNAc-ase activity of the intracellular extracts
of 2232 clones was quantified in 96-well plates (Fig. 2
and S2 in Additional file 1). The percentage of positive
clones varied between 13 and 1%, decreasing with incu-
bation time (from 24 to 72 h) at both pHs (Table 1). The
following considerations rule out the fact that the low
percentage of positive clones might be due to the loss of
the fosmid or of the insert DNA during the screening
process. The use of a chloramphenicol resistance marker
instead of ampicillin militates against the survival of cells
without fosmid in the proximity of the β-lactamase se-
creting ones. In this study, chloramphenicol was present
in the culture medium in all steps of the pipeline, main-
taining selection pressure for preservation of a fosmid
throughout. Additionally, the vector pCC1FOS has been
shown to be stable in the EPI100 E. coli strain after three
replications and 3 days of growth on solid plates without
chloramphenicol (unpublished results). Finally, F
replicon-based, single-copy fosmids such as pCC1FOS
are known to stably maintain insert DNA [45]. Thus, the
cytometric detection of such a high number of false pos-
itives is more likely due to (i) the tolerant sorting thresh-
old that was deliberately chosen to avoid missing
positive droplets; and (ii) the sorting of weakly active
clones (based on nanomolar FACS sensitivity) with high
growth rate in droplets, which were not selected after
the secondary activity screening in microplates, normal-
ized for cell growth. Besides, despite the observed
Fig. 1 Workflow of the microfluidic picoliter droplet screening of a fosmid metagenomic library. (a) A library of metagenomic clones in E. coli was
encapsulated in droplets under a Poisson distribution (λ = 0.35, i.e., 25% were singly compartmentalized) in the presence of a fluorogenic
substrate. (b) After 24 to 72 h incubation, at least 6 million droplets for each condition were sorted using FACS. The droplets exceeding a set
product fluorescence threshold (> 5-fold background) were pooled and demulsified (c) before plating the clones. On the 19,501 clones recovered
from the six droplet pools after overnight growth on agar plates, a secondary screening was performed on 372 candidates per sorting condition,
to quantify their hydrolytic activity at pH 8 and 9. Of 2232 assayed combinations, 144 clones exhibited 2 times the value of a negative clone and
were selected for further analysis. (d) The metagenomic DNA inserts (ranging from 30-40 kb) were sequenced. Assignment of clonal and partial
redundancies led to identification of novel human glycan utilization pathways. (e) The ability of the different clones to breakdown native, non-
fluorogenic human glycans was finally demonstrated by HPAEC-PAD analysis
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leakage of resorufin-β-GalNAc (at pH 8 beyond 15 h of
incubation, Fig. S1), a large number of genuine hits
could be validated by re-screening, suggesting that prac-
tical concerns about leakage can be overcome in this
way, even for long incubation times.
The success of the strategy in identifying a total of 144
active clones demonstrates that at least one cell survives
the incubation period in the droplet and the demulsifica-
tion step, and that these cells can be recovered by growth.
If more cells are recovered or if identical sequences are
identified as a result of screening at least 90 identical cop-
ies of each library member, this process results in clonal
redundancy after cell recovery from the demulsification
medium. Thus, in order to avoid the complete sequencing
of the same metagenomic clone several times over, we
first determined clonal redundancy by N- and C-terminal
sequencing of all the active clones identified after activity
quantification (Table S1 in Additional file 1). We
Table 1 Outcome of droplet-based microfluidic screening. After FACS sorting of the positive droplets and de-emulsification, cells
were plated on solid agar to recover the sorted clones. For each screening condition, the activity toward resorufin-β-GalNAc of 372
of the 22,200 clones recovered on solid plates was quantified at 37 °C in 50 mM Tris/HCl, pH 8 or 9, to select those with at least
twice the activity of the E. coli host used as negative control. Then, the clonal redundancy resulting from the bulk de-emulsification
of the hit droplets was quantified by sequencing the metagenomic insert extremities for each positive clone, in order to determine
the yield of different positive clones isolated from the initial metagenomic library of 20,000 clones
Recovery yielda (%) Positive clonesb (%) Different positive clones Positive clone yieldc (‰)
Library pH 8
24 h 146 13 14 0.7
48 h 179 8 15 0.75
72 h 94 6 9 0.45
Library pH 9
24 h 47 9 6 0.3
48 h 100 1 2 0.1
72 h 28 1 1 0.05
aRecovery yield (%) = 100 × (number of clones recovered on solid plates)/(number of positive droplets)
bPositive clones (%) = 100 × (number of positive clones in quantitative microplate assays)/(number of clones recovered on solid plates)
cPositive clone yield (‰) = 100 × (number of different positive clones)/(initial library size)
Fig. 2 Activity of the different clones quantified in liquid medium toward resorufin-β-GalNAc. Since all the clones isolated at pH 9 were also
isolated at pH 8, the activity at pH 8 (at 37 °C in 50 mMTris/HCl) of the 22 different clones identified in this study is presented in this figure.
Activity was normalized with cell growth, quantified at DO600nm before lysing the cells to extract the intracellular GHs. The negative clone Epi
(host Epi100 E. coli strain) was used as negative control
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considered sequences to be identical when N- and C-
termini were identical between two clones (on average
600 bp, which corresponds to the length of the sequences
obtained by Sanger sequencing from the vector extrem-
ities). We validated this hypothesis by complete sequen-
cing of two DNA inserts with N- and C-termini identical
to those of clone 22 and clone 8. These sequences were
strictly identical to those of clone 22 and clone 8,
respectively.
For each sorting experiment, between 1 and 15, dif-
ferent clones were obtained, giving an overall clonal
hit yield between 0.05 and 0.75‰. Comparison of
timescales (Tables 1 and S1) shows that some clones
go amiss for longer incubation (correlated to the de-
crease of the recovery yield as a result of high lysis
level at 72 h, in particular at pH 9). Under the best
screening condition (pH 8, 48 h incubation), we sorted
1.9 k droplets by FACS, recovered 3569 colonies,
picked 372 of these for the secondary screen, in
which 31 had high activity and were sequenced to re-
veal 15 unique hits. This result was obtained under
conditions that we presume to represent the optimal
balance between E. coli growth and lysis rates in
droplets, enzyme activity at basic pH, and substrate/
product leakage during the long incubation time re-
quired for spontaneous cell lysis (48 h incubation at
pH 8). The highest hit rate was three times lower
than that obtained by automated screening of the
same library for β-GalNAcase activity on solid plate
(2.3‰, from [28]). Nevertheless, sequence redundancy
had not been assessed in this previous study, which
might have resulted in over-estimation of the hit rate.
In addition, this previous conventional screening ef-
fort took 30 times longer and required 5000 times
more substrate than our microfluidics-based workflow
to explore the same sequence space, and this, without
the 90 replicates for each library member that we
screened in this work.
In order to establish that the selection outcome was
consistent with the substrate used, and to detect com-
plementary activities due to enzyme promiscuity toward
hexosaminoglycosides or to the presence of several
CAZyme encoding genes clustered in the selected meta-
genomic loci, we compared the activity of the 22 differ-
ent active clones selected by droplet-microfluidics
against 5-bromo-4-chloro-3-indolyl-β-GalNAc (X-β-Gal-
NAc) and 5-bromo-4-chloro-3-indolyl-β-GlcNAc (X-β-
GlcNAc). These chromogenic substrates have been pre-
viously used for conventional screening of this metage-
nomic library on solid plates. Interestingly, eight of the
clones were active both on X-β-GalNAc and X-β-
GlcNAc, while more than half of the different clones
were not active on either of the tested X-substrates
(Table S2 in Additional file 1). These results clearly
highlight that the CAZyme activity is affected by the
structure of the chromogenic/fluorogenic aglycone.
Identification of human glycan degradation pathways
The metagenomic DNA from the total of 22 different
clones was sequenced using high sequencing depth
(100X), ensuring reliable sequence assembly. For each
clone, one contig sized between 32,148 and 43,348 bp
was obtained. Among the 641 annotated genes, we iden-
tified 61 CAZymes including 56 GH family members,
three carbohydrate esterases (CE), and two polysacchar-
ide lyases (PL). All of the clones harbored at least one
GH sequence assigned to the GH20 and GH123 CAZy
families, which are likely responsible for the screened ac-
tivity (Table S3 in Additional file 2). However, SDS-
PAGE analysis of the E. coli cell extracts did not allow
us to highlight overproduced proteins (Fig. S3 in
Additional file 1), indicating that the specific activity of
the CAZymes is sufficiently high to detect significant ac-
tivity levels (Figs. 2, S2 and S3), despite a low yield of re-
combinant protein production. In such E. coli fosmid
clones, only some genes of the cloned loci are expressed
spuriously, likely due to the presence within the metage-
nomic sequence of σ70 promoter sequences for E. coli
[35, 46, 47]. In these metagenomic sequences, one
CAZyme was found every 13 kb, which is 3.5 times more
frequent than in the randomly sequenced human gut
metagenome [48]. Except for clone 1 that displays a
unique sequence, partial redundancies were observed for
all the contigs (Fig. 3), with 100% sequence identity on
7867 to 35,872 bp. This allowed us to define five metage-
nomic loci by contig assembly (with size between 46,158
and 72,080 bp). In total, 22 different CAZyme sequences
were identified. Repetition of one of the experiments
displayed in Table 1 (24 h incubation, pH 8) led to nearly
identical outcomes (Tables S1 and S4 in Additional file 1):
12 different hit clones instead of 14 were found, and no
other CAZyme sequence was identified (Tables S1 and S3).
This exquisite screening reproducibility demonstrates the
high-quality of the droplet assays and the beneficial effect
of the 90-fold oversampling that is feasible because of the
ultrahigh throughout possible in droplet screening.
In order to analyze the biological role of the identified
metagenomic loci in the human gut, further in-depth se-
quence analysis was performed, with activity profiling on
β-GalNAc and β-GlcNAc containing human gangliosides
and human milk oligosaccharides that share structural
similarity with intestinal mucins (Table 2, resulting from
HPAEC-PAD analyses presented in Fig. S4 in Additional
file 1). These oligosaccharides are devoid of the chromo-
phore or fluorophore which could affect activity, and
represent physiological substrates that mucosal bacteria
encounter in their habitat. Five clones (clone 1, clone 2,
clone 3, clone 4, and clone 5) were selected to represent
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the diversity of all the CAZymes identified after the se-
quencing step. Selection was based on the presence
within their sequence of the highest number of CAZyme
encoding genes, which could be involved in the clone
phenotype (clone 2 and clone 4), or on their high contig
length and activity level on the screening substrate
(clone 3 and clone 5). These representative metagenomic
loci were assigned to the Bacteroides genus, with marked
syntenies with genomes of human gut cultivated strains
(Fig. 3), highlighting likely horizontal gene and loci
transfers between gut bacteria. Indeed, horizontal gene
transfers have largely been demonstrated within the hu-
man gut microbiome, as impacting functions linked to
glycan utilization [8, 49, 50]. In addition, the presence of
mobile elements, known as main agents of horizontal
gene transfer, in some clones (clone 1, clone 4, clone 5,
clone 6, clone 7, clone 9, clone 14, clone 17, clone 20,
and clone 21) could underline this phenomenon. Hom-
ologous sequences of all the CAZyme encoding genes
identified in this study, from the clone 1, clone 2, clone
3, clone 4, and clone 5 loci, were found in both gene cat-
alogs of the human gut microbiome [51, 52]. The gene
abundance counting in the human gut microbiome of
760 individuals, from a European cohort comprising
healthy individuals and IBD patients [51], revealed two
categories of sequences (Fig. 4).
Fig. 3 Gene organization and partial sequence redundancy of the hit clones. The best synteny with referenced genomes is indicated with
gray bars
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Table 2 Summary of the ability of the hit clones to hydrolyze human glycans. Cell extracts, containing one (clone 3 and clone 5) or
several GHs (clone 1, clone 2, and clone 4), were incubated with 2 mM host-derived oligosaccharides for 24 h at 37 °C in 50 mM
sodium phosphate buffer pH 7, before analysis by HPAEC-PAD (detailed in Fig. S4). The tested oligosaccharides, which share
structural homologies with intestinal mucins, were the aGM2, GM2, tGB4, and GM1a ganglioside sugars, and the HMOs lacto-N-triose
(LNT2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT). The E. coli Epi100 screening strain constitutes the negative control. The
purified Uhgb_GH123 enzyme isolated in clone 5 was tested in the same conditions on these substrates, using 2 μM of enzyme.
Keys: -, no hydrolysis; +, partial hydrolysis; +++, complete hydrolysis; blue circle, Glc; yellow circle, Gal; blue square, GlcNAc; yellow square, GalNAc; purple
diamond, neuraminic acid
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Fig. 4 Abundance and prevalence in the human gut microbiome of the newly discovered CAZymes encoding genes. Gene abundance (a,
relative abundance of genes in samples that contain them) and prevalence (b, percentage of subjects whose microbiome contains the target
genes) were determined in the gut metagenome of 760 European subjects including 401 healthy and 359 IBD affected individuals [51]. Asterisks
indicate significantly different prevalence between the two clinical status groups (p value < 10−5)
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Highly abundant host glycan degradation pathways in the
gut microbiome
The clone 1, clone 2, and clone 3 genes encoding
CAZymes are highly abundant and prevalent in the hu-
man gut microbiome, regardless of the medical status of
the individuals (Fig. 4). Indeed, their average relative
abundance in the human gut metagenome is in the same
range as that of the most abundant genes of the catalog
[51], and these genes were found in more than 85% of
the individuals. Clone 1 shares synteny with the genome
of Bacteroides uniformis NBRC 113350, and the GH20
shares more than 99% identity (100% coverage) with its
GH20 Bun01g_36790 (GenBank ID: BBK89309.1). In
addition to the GH20, the clone 1 contig also contains
GH84 and GH24 sequences. Both the GH20 and GH84
families contain β-N-acetylhexosaminidase members, in
particular β-N-acetylglucosaminidases, while character-
ized members of family GH24 are all lysozymes. Even if
the clone 1 extract exhibits a weak activity on the
screening substrate resorufin-β-GalNAc, it produces
much more β-GlcNAcase than β-GalNAcase activity, be-
ing active only on X-β-GlcNAc and on the human milk
oligosaccharide LNT2 but not on GalNAc containing
human glycans (Fig. S4a and Table 2). This activity pro-
file is consistent with a role of the GH20, the GH84, or
both enzymes in GlcNAc/GalNAc breakdown.
The clone 2 and clone 3 sequences both present syn-
teny with two loci from Bacteroides vulgatus ATCC
8482. Clone 2 includes the predicted PUL from BVU_
4133 to BVU_4145 referred in the PUL database
(PULDB, [53]), which contains six GH-encoding genes
(one GH33 and GH92, two GH2, and three GH20). This
CAZyme-rich locus has also recently been isolated by
conventional screening of the same library [28] (clone
14 N11, corresponding to clone 10 in the present study,
of which the sequence is largely covered by that of clone
2), and proved to be involved in the alteration of the
colon mucus structure using lectin binding assay. The
present PUL shows a close gene organization to the re-
cently characterized N-glycan PUL from BT0451 to
BT0461 with relatively high sequence identity between
homologs from 64 to 79% (with 96-100% coverage) [23]
(Table S3). Here, we refined the mechanisms of degrad-
ation of this complex mucus matrix by demonstrating
that this locus is involved in the hydrolysis of a large
panel of human glycans of defined structures (Fig. S4a-
f). Clone 2 indeed hydrolyzed terminal β-(1,3)-linked
GlcNAc and GalNAc motifs regardless of the linkage β-
(1,4) or β-(1,3), and also β-(1,4)-linked Gal residues, but
not β-(1,3) linked ones. In particular, the GM2 ganglio-
side was completely hydrolyzed, probably due to the
presence of the GH33 enzyme which might be respon-
sible for the hydrolysis of the neuraminic acid residue,
while GH20 and GH2 might be involved in the
hydrolysis of GlcNAc/GalNAc and of Glc/Gal, respect-
ively. These results are in agreement with the activities
observed for the homologous enzymes individually char-
acterized by Briliute et al. [23]. The second locus
assigned to B. vulgatus, namely the clone 3 sequence,
contains only one GH20 encoding gene. This enzyme
could not have been identified by conventional screen-
ing, clone 3 (and the other clones containing this locus)
being inactive on X-GalNAc or GlcNAc substrates
(Table S2). In addition, as for clone 1 and clone 5, this
locus could not have been retrieved by sequence-based
mining of the PULDB, in which it is not listed since it
does not include any SusD encoding gene. However,
here, we show that this highly abundant sequence may
play a key role in the bacterial degradation of host gly-
cans, especially those containing terminal β-(1,3) linked
GlcNAc (like LNT2), and also terminal β-(1,3) linked
GalNAc (like tGB4) (Fig. S4a and c, Table 2). The GH20
gene of clone 3 probably encodes a secreted protein or a
lipoprotein, since signal peptidase I (SpI) and II (SpII)
cleavage sites were predicted in its sequence. If it is a
lipoprotein, it is likely attached to the outer membrane,
since there is no aspartic acid in position +2 after the
SpII cleavage site. The promiscuity of this GH20 toward
β-linked hexosaminides, and its cellular location, prob-
ably confer an ecological advantage to the species produ-
cing it in the mucosal habitat by allowing it to forage on
a large panel of human glycans. This could explain the
high prevalence and abundance of this sequence in the
microbiome.
Highly prevalent pathways in inflammatory context
The second group of sequences contains the clone 4 and
clone 5 contigs. Except for the two highly prevalent
genes encoding mobile elements (clone 4_ORF10 and
clone 5_ORF3, both homologs to gene DLM022_
GL0145524 of the catalog which is present in 86% of the
subjects) distributed among intestinal bacteria (princi-
pally in Bacteroides, Prevotella, Odoribacter, Porphyro-
monas, Alistipes spp., and the Mucinovorans pathogens),
the clone 4 and clone 5 sequences are much less preva-
lent in the gut microbiome than those of clones 1-3 (Fig.
4). Nevertheless, many genes of the clone 4 and clone 5
loci, including GalNAc active enzymes, are significantly
more prevalent in IBD affected individuals (p value <
10−5). They both share high synteny with Bacteroides
plebeius DSM 17135 genome. Clone 4 contains nine
CAZyme-encoding sequences (three GH2, GH20, GH42,
GH28, one bifunctional GH105-CE12, PL11, and PL26),
corresponding to the predicted PUL from BACPLE_
00240 to BACPLE_00256 of the PULDB (Fig. 3), to
which no substrate had been associated yet [53]. The
combination of CAZy modules in this PUL is very simi-
lar to those of PULs from Bacteroides thetaiotaomicron
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VPI-5482 (from BT4145 to BT4183) and Bacteroides
xylanisolvens XB1A (from BXY_32120 to BXY_32390)
which target type I rhamnogalacturonan, a component
of pectins [54, 55]. In the human gut, the clone 4 locus
thus probably targets this dietary glycan. The β-
hexosaminadase (Fig. S4a-c) activities that we detected
for clone 4 may be due to substrate promiscuity of one
or several of the produced CAZymes, since the presence
of GlcNAc or GalNAc in pectins has never been shown.
Besides, the clone 5 locus, which contains only one
GH123 sequence, is not listed in the PULDB since it
does not include any SusD encoding gene. In addition,
all the clones producing this GH123, which were the
most frequently retrieved from this screening (at all in-
cubation times and both pH, Fig. 3 and Table S1), were
inactive on X-GalNAc or X-GlcNAc (Table S2) and
could thus not have been identified either by conven-
tional screening. Interestingly, the high prevalence of
this GH encoding gene correlates with IBD incidence,
since it is found to be twice as prevalent in the IBD af-
fected individuals (42% of the IBD subjects, versus 21%
of the healthy ones). The specificity of this key enzyme
was thus further investigated at the molecular level.
Uhgb_GH123, a prevalent ganglioside-degrading enzyme
in the gut microbiome of IBD patients
The clone 5 sequence encoding the GH123 enzyme
(named Uhgb_GH123) shares 100% identity (and full se-
quence coverage) with BACPLE_01933 (GenBank ID:
WP_007561385.1), a gene encoding a DUF4091 domain-
containing protein from B. plebeius DSM 17135. Its se-
quence similarity with the three characterized GH123
members is low, with 53% identity with BvGH123 from
B. vulgatus ATCC 8482 [56], 35% with NgaP from Pae-
nibacillus sp. TS12 [57], and 30% with CpGH123 from
Clostridium perfringens ATCC 13124 [58]. We searched
for BvGH123, NgaP, and CpGH123 sequences in the
microbiome, in order to compare their prevalence with
that of Uhgb_GH123. This analysis revealed that no
NgaP homolog sequence was found in the gene catalogs
of the human gut microbiome and that Cp123 encoding
gene is found in only 4% of the subjects (Fig. S5 in Add-
itional file 1). By contrast, we show that the BvGH123
encoding gene is highly prevalent (88% of the subjects)
and abundant, regardless of the health status of the indi-
viduals, confirming the prominence of B. vulgatus in the
gut. Only the Uhgb_GH123 sequence is more prevalent
in the IBD cohort (42% versus 21% of the healthy indi-
viduals), highlighting its possible implication in gut in-
flammation. This gene was also abundant in the
metagenomic DNA sampled in the present study, since
it was found in seven of the 22 different clones identi-
fied, representing 21% and 55% of the positives clones
retrieved at pH 8 and pH 9, respectively (Table S1). This
might be due to the fact that this sample was issued
from a patient with suspected colon cancer, a pathology
resulting from chronic intestinal inflammation.
In order to characterize Uhgb_GH123 at the molecular
level, its encoding gene was subcloned to produce a sol-
uble protein with a N-terminal (His)6 purification tag.
The specificity of the purified enzyme was characterized
by determining its kinetic parameters on various syn-
thetic p-nitrophenyl glycosides. The purified Uhgb_
GH123 was only active on pNP-β-D-GalNAc and pNP-
β-D-GlcNAc. No activity was observed on pNP-α-D-
GalNAc, pNP-α-D-GlcNAc, pNP-α-D-Glc, pNP-β-D-
Glc, pNP-α-D-Man, and pNP-β-D-Man. Uhgb_GH123
displays a pH optimum of 5.5, a temperature optimum
of 30 °C, and a 213-fold higher catalytic efficiency on
pNP-β-D-GalNAc than on pNP-β-D-GlcNAc (Table S5
in Additional file 1). This preference for β-
galactosaminides versus β-glucosaminides is also a trait
of BvGH123 [56], indicating that these two enzymes
might act on the same physiological substrates. How-
ever, the ability of BvGH123 to hydrolyze human glycans
of defined structures has never been studied.
In order to identify the physiological substrate of
Uhgb_GH123, its specificity toward host-derived glycans
harboring β-linked N-D-acetylgalactosamine or β-linked
N-D-acetylglucosamine residues was determined using
HPAEC-PAD analysis of hydrolysis products (Table 2,
Fig. S4g). Like the cell extract of clone 5 (Fig. S4a-c),
which only contains this GH, Uhgb_GH123 cleaved the
terminal β-D-GalNAc residue of aGM2 and tGb4 sub-
strates, with no significant preference for β-(1,4) or β-(1,
3)-GalNAc linkages. GM2 was resistant to enzymatic hy-
drolysis, indicating that the presence of the neuraminic
acid residue prevents accommodation of sialylated sub-
strates in the enzyme active site.
Discussion
Ultra-high throughput sorting of intracellular enzymes
In this study, we have shown the screening of 20,000
library members with 90-fold repetition, covering 0.7Mb
of metagenomic DNA (the equivalent of 200 bacterial
genomes) in 4 min. This is 2600-fold faster than an auto-
mated colony screen. This extensive screening experi-
ment (under six different conditions) was possible with
less than 0.01 mg of fluorogenic substrate (at a cost of
$0.1), while an automated colony screen or a robotic
liquid handling experiment would have consumed 900-fold
(assuming 7.2mg for the 9 large screening plates required
to screen 20,000 clones [29]) and 2000-fold more substrate
(assuming 100 μl in each well of a 348-well plate), respect-
ively. In addition, by using microfluidics, it was pos-
sible to screen each clone on average 90 times
(resulting in 1.8 million assays), which contributed to
excellent reproducibility. Disregarding the cost of
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instruments (~ $39 k for a microfluidic set-up vs
$300-750 k for an automated robotic system) the con-
sumable costs required to perform 1.8 million assays
were $346 in our microfluidic assay, compared to ~
$112 k using a robotic system with 384-well plates
(Table S6 in Additional file 1). By using this efficient
technology, success is more likely, as genuine hits are
bound to show up when tested multiple times, even if
the detected activity is close to background. This ver-
satile approach could also be used with any other
chromogenic/fluorogenic substrates employing analo-
gous sorting strategies, such as absorbance-activated
droplet sorting (AADS) [59]. Here, we used resorufin-
β-GalNAc to mimic the structure of human-derived
glycosides. The only other commercial fluorogenic
substrates containing residues highly abundant in hu-
man glycans, 4-methylumbelliferyl-α-Neu5Ac and 4-
methylumbelliferyl-α-Fuc, were not compatible with
our droplet-based assay, in which cell growth, lysis
and substrate hydrolysis were performed in one single
step. Indeed, in order to detect the signal, the fluores-
cence of 4-methylumbelliferyl would have to be 100-
fold more intense, which could be achieved by adding
a pH 10.7 buffer [60]. However, this would have pre-
vented cell growth and enzyme activity, since most
CAZymes from the human gut microbiome are in-
active above pH 9 [8]. To avoid the use of chemically
modified substrates that could result in screening bias,
coupled assays involving unlabeled substrates and
various pH ranges could also be developed.
In practice, our approach is based on E. coli division
and partial spontaneous lysis in droplets, allowing the
release of intracellular enzymes into the extracellular
medium, where they would encounter the substrate. In
addition, maintaining living cells in the same droplet as
lysed cells allowed their function as a marker for the
tested clone that can be recovered efficiently after ampli-
fication of recovered cells by growth. We demonstrate
that now, multiple intracellular enzymatic activities pro-
duced from long DNA (meta)genomic loci, cloned into
low copy vectors (such as fosmids), can be screened by
droplet-microfluidics, widening the possibilities for func-
tional library screening at ultrahigh-throughput beyond
previous campaigns using high copy plasmids. This set-
up will make it possible to employ a variety of vectors
without requiring a PCR step for recovery sequence in-
formation. PCR recovery of fosmids has indeed never
been performed in activity-based metagenomics, al-
though it is theoretically possible to amplify several kbp
by a rolling-circle process [61]. After overcoming the
previous limiting requirement of high copy plasmids for
recovery [33], new applications can be imagined, since
most metagenomic resources are sequences cloned into
fosmid E. coli libraries [62, 63]. Likewise, bacterial
artificial chromosomes (BACs) or plasmids with low
DNA copy number should also become amenable to
droplet screening. If growth can be spatially adjusted, an
extension of this work flow to any expression host [64]
is also conceivable. Finally, in addition to single enzyme
screening, ultra-high-throughput discovery and com-
binatorial engineering of complex metabolic pathways is
now practically possible.
The new workflow is extremely economical and may
fundamentally shift the effort in metagenomic explor-
ation from screening (which is expensive in terms of
time, equipment, handling personnel, and reagents) to a
format that yields experimental hits in an afternoon. Im-
plementation of such a procedure is straightforward—re-
quiring simple use of pumps for droplet formation—and
replaces the delicate handling of a sorting chip by a
commercially mature instrument, a flow cytometer. Ac-
cess to this technology should therefore allow a much
wider circle of non-specialist users to engage in func-
tional metagenomics or in metabolic pathway engineer-
ing. Instead of experimental screening, bioinformatic
analyses and confirmation of hits by detailed studies
may henceforth become the rate-limiting steps in a dis-
covery workflow. The successful identification of 22
human-glycan degrading clones in this proof of concept
study underlines the validity of our approach, in particu-
lar the ability to screen multiple copies of each library
member separately, which provides a very robust and re-
liable assay. Functional information was readily obtained
despite low expression of fosmid DNA and its difficult
recovery—with both problems solved by cell growth in
droplets. The remaining practical obstacles can also be
solved: for example, the clonal redundancy was partially
a consequence of having to grow cells in droplets (to in-
crease enzymatic turnover signal and for better recov-
ery), but this complication is easily solved by sequence
analysis, by a secondary screen to eliminate clones with
the same functional profile, or even by droplet isolation
in microtiter plates, which can be performed by FACS.
Capture and characterization of human glycan
degradation pathways
The quality of the data generated at ultra-high through-
put allowed us to rapidly gain insight into the functional
potential of the mucosal microbiota, and to decipher,
from the ecosystemic to the molecular levels, aspects of
their relationships with the host.
Revealing the role of Bacteroides species in human glycan
degradation and correlation to gut inflammation
The taxonomic annotation of the large metagenomic loci
we were able to capture was based on that of 30 genes
per locus on average. This annotation is thus much
more accurate than that of small contigs containing only
Tauzin et al. Microbiome           (2020) 8:141 Page 12 of 20
one gene, like those obtained by sequence-based metage-
nomics [51].
In this study, all the identified metagenomic loci were
assigned to the Bacteroides genus. However, the
screened metagenomic library contains DNA fragments
from other genera. Analysis of the 16S rDNA from the
metagenomic DNA before cloning indeed demonstrated
that the sampled mucosa-associated microbiota displays
a phylogenetic make up resembling that of ileum and
colonic samples [65], with 52% Firmicutes (in particular
Ruminococcus bromii, Faecalibacterium prausnitzii,
Ruminococcus lactaris, Ruminococcus gnavus, Roseburia
intestinalis, and Eubacterium spp. as dominant OTUs),
40% Bacteroidetes (in particular Bacteroides vulgatus,
Bacteroides stercoris, Prevotella spp. oral, and Prevotella
ruminicola), and 8% others. Besides, we have previously
shown that E. coli is able to successfully express genes
and produce functional proteins from Gram positive and
Gram negative gut bacteria from various genera [8]. The
particular library used in this study was screened for the
degradation of dietary fibers (prebiotics or plant cell wall
polysaccharides), and the sequences were assigned either
to Bacteroidetes (53% of the sequenced clones), or Firmi-
cutes (47%) [27, 66], while most of the hit clones belong
to Bacteroidetes (97%) when the screening targets the
degradation of host glycans ([28]; present study). This is
in agreement with the ability of Bacteroidetes to forage
on mucin glycans and/or HMOs [1, 54, 67–72]. Never-
theless, this comparison does not mean that only Bacter-
oides species can degrade host glycans containing β-
linked GalNAc residues, nor that known host-glycan de-
grading species from other genera (like Akkermansia
muciniphila [73, 74] or Ruminococcus gnavus [75]) are
absent in the mucosal ileal microbiota. For example, we
detected the presence of Ruminococcus gnavus in our
starting sample, but no sequence from this particular
species was recovered after screening. This paradoxical
observation might be due to the cloning bias described
for large-insert metagenomic libraries, resulting in under
representation of species with low G + C content, such
as most Firmicutes [63]. In addition, we have previously
shown that metagenomic gene expression in fosmid E.
coli clones is spurious [35], as explained above. Finally,
some human glycan degrading enzymes might not have
been identified under our screening conditions. Indeed,
some types of CAZymes are inactive toward chemically
modified sugars [76]. Additionally, the intestinal pH
ranges between 5 and 7 [77], suggesting that most en-
zymes from the microbiome would have pH optima
below neutral.
Here, we highlighted four loci that share significant
similarity with B. vulgatus ATCC8482 and B. plebeius
DSM17135 loci. Bacteroides vulgatus is one of the most
abundant bacterial species in the human gut. It was
shown to be overabundant in several IBD studies [78–
82], and described as a pathobiont due to its ability to
invade gut epithelial cells and induce IBD in response to
host and/or environmental triggers [83, 84]. Bacteroides
plebeius does not seem to have the same impact on the
intestinal mucosa in the inflammatory context. Mondot
et al. (2015) have shown that its abundance may be asso-
ciated with homeostasis and remission in Crohn’s dis-
ease patients after ileocolonic resection [85].
IBD are characterized by an unbalanced composition
of the intestinal microbiota, termed “dysbiosis” [2, 86],
and by an uncontrolled inflammatory response to lu-
minal content [87]. In addition, in IBD the intestinal
barrier function is severely impaired, with a thinner
outer mucus barrier [88], and the layer closest to the
epithelium is invaded by commensal bacteria or patho-
gens, including adherent-invasive E. coli (AIEC) in the
ileum form of Crohn’s disease [41, 89]. Several species as-
sociated with IBD, like Ruminococcus gnavus, are efficient
mucus degraders [20, 90]. However, despite this evidence,
the causality links between dysbiosis, alteration of the
mucus layer by gut bacteria and chronic inflammation in
IBD, are not yet fully established, especially in humans
[42]. The present in vitro results allow us to extend the
still short list of human glycan degraders, and to revisit
the catabolic potential of B. vulgatus and B. plebeius.
Moreover, the high prevalence and abundance of the
metagenomic loci identified here indicate that the en-
zymes they encode are key actors in functioning micro-
biota. This result also underlines the huge gap existing
between our knowledge of glycan degrading pathways in
microbial ecosystems and their real diversity. This is espe-
cially true for the human gut bacterial pathways targeting
host glycans, which still constitute the dark matter of the
microbiome, having been much less studied than plant
polysaccharide degrading pathways.
Ganglioside degradation and implication for human health
To date, only a few pathways of ganglioside degradation
by commensal human intestinal bacteria have been de-
scribed [91]. In family GH123, the only characterized
ganglioside degrading enzymes are CpGH123 (from the
human pathogen C. perfringens ATCC 13124) [58], and
PaGH123 (from the soil bacterium Paenibacillus sp.
TS12) [57], which were shown to hydrolyze the GA2
(GalNAc-β1,4-Gal-β1,4-Glc-β1,1-Ceramide) and Gb4
(GalNAc-β1,3-Gal-α1,4-Gal-β1,4-Glc-β1,1-Ceramide)
structures. BvGH123 (from the human gut bacterium B.
vulgatus ATCC 8483) was only tested on the chromo-
genic substrates X-β-GalNAc and X-β-GlcNAc. These
three enzymes are the only characterized members of
the GH123 family up to date. In the present study, we
identified and characterized a new GH123 member,
named Uhgb_GH123. We demonstrated that this
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enzyme is able to hydrolyze different gangliosides, in-
cluding aGM2 and tGb4, which have structures similar
to the GA2 and Gb4 ceramides, respectively.
Gangliosides are glycolipids that play major roles in
signal transduction, cell adhesion, antigen recognition,
and protein trafficking. In humans, they mostly occur
in brain tissues [92] but they are also present in extra-
neural locations (spleen, liver, intestinal, and urinary
tract epithelial cells). They are also components of
foods such as human breast milk and dairy products.
Gangliosides in the intestinal mucosa play a crucial role
by preventing inflammation, susceptibility to pathogens
and loss of gut barrier integrity, and accelerated gan-
glioside catabolism contributes to pathogenesis of IBD
[93, 94]. These observations are in accordance with the
fact that we found the Uhgb_GH123 encoding gene sig-
nificantly more prevalent in the microbiome of IBD pa-
tients than in that of the healthy individuals. The
Uhgb_GH123 sequence is not a gene biomarker by it-
self, since it can be found in low abundance in some
healthy individuals. In addition, we do not know
whether this high prevalence in IBD is a cause or
merely a consequence of the disease. Nevertheless, the
high prevalence in IBD of the genes encoding this mul-
tispecific ganglioside degrading enzyme and its homo-
logs suggests that they may play a role in the
inflammatory process. The results of our in vitro meta-
genomic study will thus have to be held against those
of in vivo studies. The objective of these analyses will
be to further decipher the role of Uhgb_GH123 and the
other human glycan degrading enzymes identified here
in the breakdown of intestinal gangliosides and mucins
and, more generally, in the host-microbiota interaction
in the context of IBD.
Conclusion
Activity-based functional metagenomics is a powerful
approach to boost the discovery of functions in micro-
biomes. However, the conventional methods are limited by
the large amounts of substrate and culture medium that are
required for automated screening on agar plates or in
micro-plates. Here, we developed a generic droplet
microfluidics-based method to speed up and miniaturize
the screening process by several orders of magnitude, while
being compatible with any type of library and metagenomic
DNA size. The proof of concept was established by
mining the mucus-associated human gut microbiome
for host-glycan degrading enzymes, highlighting
novel pathways of metabolization of human glycans
by gut bacteria, in particular pathobionts. These re-
sults offer opportunities to facilitate future holobio-
mics studies, to achieve a better understanding of
the host-microbiota interactions.
Methods
Metagenomic library construction
The metagenomic library has been constructed in a pre-
vious study [26]. Briefly, a healthy distal part of the
ileum was collected from a 51-year-old male patient
undergoing colonoscopy and surgery for suspected lower
colon cancer, after he had been submitted to a cleansing
preparation. The patient did not receive any antibiotics
or other drugs during 6 months before sampling. A seg-
ment of 2 cm2 was obtained from a healthy zone, imme-
diately frozen and kept at −80 °C until processing. The
ileal mucosa was scraped and an enriched bacterial frac-
tion was recovered by applying the method described in
Courtois et al. [95]. The metagenomic DNA was ex-
tracted as described by Tasse et al. [8]. A 16S rDNA li-
brary was performed using S-D-Bact-0350F-a-S-20 (E.
coli numbering) CT CCTA CGG GAG GCA GCA GT
[96] and 1392R GC G GTG TGT AC A AG A/G CCC
[97]. Metagenomic DNA fragments sizing from 30 to 40
kb were isolated as described by Tasse et al. [8], and
cloned into the pCC1FOS fosmid (Epicenter Technolo-
gies). EPI100 E. coli cells were then transfected to obtain
a library of 20,000 clones covering 800Mb of metage-
nomic sequences. The library was stored in micro-plates
to be screened either by conventional automated
methods or by using droplet microfluidics. To do so, re-
combinant clones were transferred to 384-well microti-
ter plates containing a Luria-Bertani (LB) medium,
supplemented with 12.5 μg/mL chloramphenicol and 8%
(w/v) glycerol. After 22 h of growth at 37 °C, the plates
were frozen and stored at −80 °C.
Microfluidics-based screening
Materials
The materials used were purchased from Sigma Aldrich
unless otherwise indicated. Fluorinated oils HFE-7500
were purchased from 3M Novec and the 008-
Fluorosurfactant from RAN biotechnologies. Resorufin-N-
acetyl-β-D-galactosamine was purchased from Marker-
gene (M1037), EDTA-free protease inhibitor from Roche
(11873580001), Lysonase (71230), and BugBuster (70921-
4) from Millipore.
Device fabrication
All microfluidic devices for monodisperse emulsion for-
mation were produced using soft lithography as previ-
ously detailed [98]. A flow-focusing design was used
(20 μm intersection width and 15 μm channel height)
with three (for droplet generation, Fig. S6a in Additional
file 1) or two inlets (for the double emulsion, Fig. S6b).
The designs for these chips are freely available to down-
load as CAD-compatible or png files from the DropBase
Repository of droplet microfluidic device designs [99].
The masters were built by applying a layer of SU-2025
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(15 or 20 μm) on a 3 silicon wafer using conventional
lithography. The master was coated with a mixture of
poly(dimethyl)siloxane (PDMS, Slygard 184) and curing
agent (Slygard 184) in a ratio of 10:1 (w/w). After degas-
sing and curing (overnight, 65 °C), the PDMS devices
were removed from the master, and holes for tubing
connections were created using a biopsy punch (1 mm,
PFM). The devices were then bonded onto a glass slide
by treating with oxygen plasma (20s, Diener Femto
plasma asher). For the hydrophobic chips, the triple inlet
device was immediately filled with a 1% (v/v) Tri-
chloro(1H,1H,2H,2H-perfluorooctyl)silane (FOTS) in
HFE-7500 solution to provide a hydrophobic coating.
The hydrophobic chips were incubated to ensure good
bonding between PDMS and glass (65 °C, O/N). Once
bonded, the double inlet devices were incubated to im-
prove bonding (65 °C, 2 h), they were then treated with
oxygen plasma a second time and immediately perfused
with PBS to make the chips hydrophilic. The hydrophilic
devices were kept in a hermetically sealed and humid
box and were used within 1 week.
Metagenomic library preparation
Clones were arrayed individually from micro plates on
solid plates to avoid growth bias, which could have oc-
curred in liquid culture. After overnight growth at 37 °C,
the cells were scraped, retrieved in LB medium supple-
mented with 12.5 μg/mL chloramphenicol and 8% (w/v)
glycerol, and stored at -80 °C. In order to refresh the
clones before screening, 250 μL were plated on LB agar
medium supplemented with 12.5 μg/mL chlorampheni-
col, and grown overnight at 37 °C. All the colonies ob-
tained were scraped off the plate and the plate was
washed three times with 3 × 3mL liquid LB containing
12.5 μg/mL chloramphenicol. The cells were harvested
by spinning them down to form a pellet (4000 g for 10
min), the supernatant was discarded and the cells re-
suspended in recovery medium (F98226-1, Lucigen).
The OD600nm of the cell suspension was measured and
diluted in buffer (100 mM Tris-HCl pH 8 or 9, 100 mM
NaCl, 12.5 μg/mL chloramphenicol and EDTA-free pro-
tease inhibitor, Roche) containing Percoll at 25% (v/v) in
order to avoid aggregation of cells. This cell suspension
was fed into the microfluidic device to form droplets
(see details below) with a droplet occupancy (λ) of 0.35
when diluted 1:1 on chip with substrate (resorufin-β-
GalNAc at 40 μM) in a 2 pL droplets following a Poisson
distribution (resulting in about 70.5% of empty droplets,
25% with single cell, and 4.5% with higher occupancy).
Generation of single emulsions
For the generation of monodisperse microdroplets, a
microfluidic device with a double aqueous inlet flow-
focusing junction was used (Fig. S6a). The device was
connected via polythene tubing (0.38 mm ID, 1.09 mm
OD, Smiths Medical) to syringes (100 μL, 500 μL, or 2.5
mL SGE glass syringes), 2500 μL SGE which were driven
by syringe infusion pumps (Nemesys low pressure
pumps, Cetoni). Droplet formation was monitored using
a high-speed camera (MiroEx2 Phantom camera, Vision
Research). Water-in-oil single emulsions, containing
resorufin-β-GalNAc (Fig. S6a inlet 2) and cells (Fig. S6a
inlet 1), were formed in a hydrophobic flow-focusing de-
vice with channel dimensions of 15 μm height/120 μm
width. The carrier oil phase was HFE 7500 (3M) with
0.5% (w/w) surfactant (008-Fluorosurfactant, RAN bio-
technologies) (Fig. S6a inlet 3). Flow rates were 1 μL/min
total for the aqueous phases (cells and substrate) and
8 μL/min for the carrier oil phase. Immediately after the
droplet generation, the droplets were stored in a 0.5 mL
tube containing HFE-7500, 0.5% RAN surfactant (Fig.
S6c and d).
Collection and incubation chambers
Collection chambers are a simpler version of a previ-
ously published design [100] (Fig. S6c and d). A 0.5-mL
Eppendorf tube was inverted and glued onto a glass slide
(Fig. S6c). Two holes were punctured using a 1 mm bi-
opsy punch (PFM Medical), into which PTE tubing
(0.38 mm ID × 1.09 mm OD) was inserted. The chamber
is filled with carrier oil (HFE-7500, 0.5% RAN), and the
tubing at the pinnacle of the tube connected to the chip
outlet to collect the droplets (Fig. S6d1), with the lower
tubing draining into an oil waste Eppendorf tube. Once
the droplet generation was stopped, the lower tubing
was inserted into a syringe which stops the flow. For re-
injection (Fig. S6d2), the syringe was attached to a pump
to allow the droplet to flow back up through the tubing
and into a hydrophobic flow-focusing device (Fig. S6b).
Generation of double emulsions
Microfluidic double emulsions were generated as previ-
ously described [38] (Fig. S6e). The formation of water-
in-oil-in-water double emulsions was performed in a
hydrophilic microfluidic device (15 μm height/20 μm
width, Fig. S6b). The aqueous carrier phase consisted of
Tween 80 (1%, w/w) in 150 mM NaCl solution. The
single emulsion was injection into the central inlet dir-
ectly from the collection chamber. The double emulsion
was collected in a 1.5-mL Eppendorf tube (Movie S1 in
Additional file 3) and incubated at 37 °C for 24, 48, or
72 h, without agitation to allow cell growth.
Flow cytometric analysis of double emulsion droplets and
cell recovery
Double emulsions were filtered (Ø 30 μm; sterile Cell-
Trics®filters) into FACS tubes, diluted in buffer (Tween
80, 1%, w/w; 150 mM NaCl), and sorted by FACS
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(MoFlo Astrios, Beckman Coulter) using Tomato 561-
579/16 for fluorescence selection. Flowing Software (ver-
sion 2.5.0, Cell Imaging Core, Turku Centre for Biotech-
nology) was used for data analysis. Double emulsion
populations were gated on logFSC/logSSC (Fig. S6f, gate
R1). The sorted droplets (Fig. S6g, gate R3) were care-
fully de-emulsified by adding recovery medium (500 μL,
containing 1% glycerol on top of the droplets) and
breaking the emulsion by adding 50 μL of PFO to the oil
phase. The recovered material was plated on LB agar
plates containing 12.5 μg/mL chloramphenicol and incu-
bated overnight at 37 °C.
Protein production and purification
First, the Uhbg_GH123 encoding gene was PCR-amplified
from the metagenomic clone 5 using the Phusion® high-
fidelity DNA polymerase (New England Biolabs). The
primers used were clone_5_ORF28_for (GGCAGCCATA
TGGCTAGCcaggcagaaaagtttccattgg) and clone_5_ORF28_
rev (GTGGTGGTGGTGCTCGAGttacatctcattgagcaatgc).
After PCR amplification, the open reading frame coding
for the GH123 enzyme was subcloned into the pET28a ex-
pression vector using Gibson Assembly® Master mix. The
recombinant plasmid pET28a_GH123 was used to trans-
form E. coli BL21 star (DE3) competent cells. For protein
expression, one individual colony was grown in LB (con-
taining 50 μg/mL kanamycin) at 37 °C until the OD600nm
reached 0.5. Then, expression was induced by adding
isopropyl-β-D-thiogalactoside (1mM) for 4 h at 37 °C.
Cells were harvested by centrifugation, re-suspended in
purification buffer (20mM TrisHCl pH 8, 300mM NaCl)
containing 0.5mg.mL−1 lysozyme to reach an OD600nm of
80. After incubation at 37 °C for 1 h, the suspension was
frozen 15min at −80 °C and then defrosted. The samples
were then centrifuged and the cell lysate was loaded on af-
finity chromatography resin (TALON®). Unbound proteins
were washed with purification buffer containing 5mM
imidazole before final elution with buffer containing 200
mM imidazole. Protein concentration and buffer exchange
was performed by using Millipore Amicon Ultra-15 Centri-
fugal Filter Concentrators (cut-off 10 kDa), and the elution
buffer was changed to 50mM sodium phosphate pH 7 for
storage. The concentration of the purified protein was
quantified using a NanoDrop™ 2000 spectrophotometer
(Thermo Fisher Scientific) with an extinction coefficient ε
of 151,635, determined using ProtParam [101].
Enzymatic assays
Substrates
pNP-substrates were purchased from Carbosynth. GalNA
cβ1-4Galβ1-4Glc (aGM2), GalNAcβ1-4(Neu5Acα2-3)Galβ1-
4Glc (GM2), Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc
(GM1a), GalNAcβ1-3Gal (tGb4), GlcNAcβ1-3Galβ1-4Glc
(LNT2), Galβ1-3GlcNAcβ1-3Galβ1-4Glc (LNT), and Galβ1-
4GlcNAcβ1-3Galβ1-4Glc (LNnT) were purchased from Eli-
cityl. X-substrates (5-bromo-4-chloro-3-indolyl-β-GalNAc,
and β-GlcNAc) were purchased from Carbosynth.
Functional profiling of the hit clones
After cell recovery on solid plates, the individual col-
onies were picked for growth in 96-deep well plates con-
taining LB media with 12.5 μg/mL chloramphenicol for
overnight incubation at 37 °C. First, the clones were
grown in LB medium, supplemented with chlorampheni-
col 12.5 μg/mL, with orbital shaking (600 rpm for deep
wells). Plate copy was performed using a Microlab NIM-
BUS workstation (Hamilton) and this step was repeated
twice to homogenize the final OD value of the cultures.
After 24 h, cells were harvested by centrifuging for 30
min at 5000 rpm., re-suspended in 300 μL 50mM Na
phosphate pH 7 buffer containing lysozyme (0.5 mg/mL
final concentration) and DNase (0.3 U final concentra-
tion) and incubated at 37 °C for 1 h. The following steps
were automated using the Genesis RSP 200 workstation
(TECAN). Cell extracts were diluted tenfold in 50mM
Tris/HCl buffer (at pH 8 or 9) containing 20 μM
resorufin-β-GalNAc, and incubated at 37 °C. The release
of fluorescent product was monitored over 2 h using an
Infinite M200 Pro (TECAN) plate-reader (excitation
wavelength 550 nm and emission wavelength 585 nm).
In addition, the hit clones were tested for activity on
solid plates containing chromogenic glycosides of vari-
ous structures. The hit clones stored in micro-plates
were spotted on OmniTray™(Thermo Fisher Scientific)
using a QPixII (Genetix) colony picker. Solid agar was
supplemented with chloramphenicol (12.5 mg/mL) and
60 μg/mL of X-substrates (5-bromo-4-chloro-3-indolyl-
β-GalNAc, 5-bromo-4-chloro-3-indolyl-β-GlcNAc). The
plates were incubated 7 days at 37 °C. The positive
clones were visually detected based on the blue color of
the colony when X-substrates were degraded.
Quantification of Uhgb_GH123 activity on chromogenic
substrates
First, the activity of the purified Uhgb_GH123 was quanti-
fied with several chromogenic substrates (pNP-β-D-N-acet-
ylgalactosamine, pNP-β-D-N-acetylglucosamine, pNP-α-D-
N-acetylgalactosamine, pNP-α-D-N-acetylglucosamine, pN
P-α-D-glucopyranoside, pNP-β-D-glucopyranoside, pNP-α-
D-galactopyranoside, pNP-α-D-mannopyranoside, and
pNP-β-D-mannopyranoside), at 37 °C during 24 h in a reac-
tion volume of 200 μL, by incubating 5 μL of Uhgb_GH123
(90 μM) in 50mM sodium phosphate pH 7 buffer contain-
ing 1mM of the pNP-substrate. Kinetic parameters of puri-
fied Uhgb_GH123 were determined by incubating in a
400 μL reaction mixture respectively 2 μL and 20 μL of
purified Uhgb_GH123 (0.60 μM and 0.03 μM) with 0.25 to
1.5mM of pNP-β-D-N-acetylgalactosamine and pNP-β-D-
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N-acetylglucosamine, in citrate buffer at pH 5.5, during 7
min and 60min, respectively. The reaction was stopped by
raising the pH to 11 by adding an equal volume of 0.2M
Na2CO3. The release of chromogenic product was moni-
tored at 405 nm using an Infinite M200 Pro (TECAN) plate
reader.
Human glycan degradation assays
The human glycan hydrolytic activities of the cell extracts
of the metagenomic clones and of the purified Uhgb_
GH123 were examined using HPAEC-PAD analysis. En-
zymatic reactions were carried out at 37 °C in a final vol-
ume of 100 μL of 50mM sodium phosphate pH 7 buffer,
by mixing 50 μL of fosmid clones cell extracts (prepared
as mentioned above) filtered at 0.22 μm, or 2 μM of puri-
fied Uhgb_GH123, with 2mM glycoside. After 24 h incu-
bation, the samples were heated 5min at 95 °C to stop the
reaction. Then the samples were diluted in water to reach
a final substrate concentration of 200mg/L for aGM2,
LNT, LNnT, LNT2, and tGb4, and 400mg/L for GM2
and GM1a, filtered at 0.22 μm and then analyzed using
HPAEC-PAD on a Dionex ICS-3000 system (Dionex)
equipped with a CarboPac PA100 column. The analyses
were carried out at 30 °C with a flow rate of 1mL/min and
the following multi-step gradient: 0–15min (0–60% B),
15–20min (60% B), and 20–25min (0% B). The solvents
used were 150mM NaOH (eluent A) and 150mM NaOH,
500mM CH3COONa (eluent B). GalNAc, GlcNAc, Gal,
Glc, Neu5Ac, and lactose were used as standards.
Sequencing
Clonal redundancy, defined as the ratio between the num-
ber of redundant clones and the total number of active
clones, was determined by N- and C-terminal Sanger se-
quencing (GATC Biotech), after fosmid extraction from
clones on agar plate supplemented with chloramphenicol
(15 μg/mL). The primers used for N- and C-terminal se-
quencing were pCC1fos_forGGATGTGCTGCAAGGC-
GATTAAGTTGG and pCC1fos_revCTCGTATGTTGTG
TGGAATTGTGAGC, respectively.
In order to perform full DNA insert sequencing, the
fosmid DNA of the different clones identified after N-
and C-terminal Sanger sequencing was extracted using
the NucleoBondXtra Midi kit (Macherey-Nagel) accord-
ing to the manufacturer’s instructions. Each purified
DNA sample was assessed for quality by agarose gel
electrophoresis giving one band only. The DNA concen-
tration was measured using a NanoDrop™ 2000 spectro-
photometer (Thermo Fisher Scientific). Sequencing of
the fosmid DNA was performed by the GeT-Biopuces
Platform (Toulouse) using the Ion Torrent S5 System.
Read assembly was performed using Masurca [102]. The
assembled contigs were cleaned from the pCC1FOS vec-
tor sequence using Crossmatch [103].
Functional and taxonomical sequence annotation
The sequence similarities between clone hits were deter-
mined using NCBI-BLASTN [104]. The contig sequences
were compared to sequences of the NCBI non-redundant
(nr) database to determine the similarities with reference
strain genomes. Taxonomic assignment of the metage-
nomic sequences was performed using the PhyloPythias
program ([105], Model type Generic 2013–800 Genera).
The open reading frames (ORFs) were predicted using the
RAST annotation server [106]. Annotation of the
CAZyme encoding genes was performed by CAZy cura-
tors following a procedure previously described [107].
First, BLASTP analysis of the predicted ORFs against the
full-length sequences included in the CAZy database [107]
allowed the automatic annotation of sequences that
aligned over their entire length without gap, if > 50% iden-
tical. Second, the remaining sequences were manually an-
alyzed by both (i) a BLAST search against individual GH,
PL, CE, CBM, and GT modules and (ii) a HMMER3
search using Hidden Markov models built for each CAZy
module family [108]. The most similar characterized
glycoside-hydrolases (GHs) were identified by BLASTP
comparison of the amino acid sequences of the GHs
found in this study with those of the characterized mem-
bers of their respective GH families, listed in the CAZy
database. Signal peptide detection was performed with the
LipoP server [109].
Analysis of gene prevalence and abundance in the
human fecal microbiome
The homolog sequences of the genes identified in this study
were searched for in both translated catalogs of 9.9 and 22
million reference genes [51, 52] using BLASTP, E value = 0,
identity ≥ 90%. The gene richness in the human gut was
assessed by recovering the occurrence frequency data of
homologous sequences of the catalog from the gene fre-
quency table in the MetaHIT cohort [51]. This cohort in-
cludes a collection of 760 samples from European adults of
various clinical status (healthy, and patients with
Crohn’s disease or ulcerative colitis) and body mass
index (lean, overweight, and obese) [110–112]. To
examine if the gene prevalence was different between
healthy versus IBD subjects, a Pearson’s chi-squared
test was performed, based on the binary variable pres-
ence or absence of the gene in subjects.
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